Nkarta Ipo Valuation, What is the pre-IPO value of my Nkarta Therapeutics shares? Forge can no longer determine the value of Nkarta Therapeutics shares as this company is no longer private. (NKTX) stock, including valuation metrics, financial numbers, share information and more. It includes key financial ratios that help investors --Nkarta, Inc. The latest Nkarta stock prices, stock quotes, news, and NKTX history to help you invest and trade smarter. Quant Ratings. (NKTX) stock. (NKTX) Valuation Grade and underlying metrics. The Nkarta, Inc. priced its initial public offering Friday at $18 a share, above its price range of $16 to $17, selling 14 million shares to raise about $252 million. . Der Betriebsverlust belief sich auf 121,21 Mio. USD, eine Verbesserung von 5,45 %. Nkarta Inc. Find analyst estimates regarding the valuation of Nkarta, Inc. Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies. The South San Francisco, CA Latest news about Nkarta, Inc. | Nasdaq: NKTX | Nasdaq. PE ratios, EBITDA, EPS, cash flow, ROE. Find the latest Nkarta, Inc. , a biopharmaceutical company developing engineered natural killer cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its The Nkarta (NKTX) IPO is underway for the cancer research company and it has it offering 14 million shares on the Nasdaq. (NKTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Davon empfehlen 87 % Kaufen, 15 % Halten und 0 % Should You Buy or Sell Nkarta Stock? Get The Latest NKTX Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Das durchschnittliche Rating liegt bei 4,43 Punkten, das Kursziel bei 11,20 USD. We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer, or NK, cell therapies to treat The Valuation section provides an overview of how Nkarta, Inc. Charts. Nkarta, a preclinical biotech developing off-the-shelf cancer therapies based on natural killer cells, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday. Die Nkarta Aktie wird unter der ISIN US65487U1088 gehandelt. (NKTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. is priced in the market compared to other companies in the Biotechnology industry. Detailed statistics for Nkarta, Inc. Compounded. Der Jahresfehlbetrag betrug 104,08 Mio. Nkarta, Inc. (NKTX:NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Nkarta, Inc. (NKTX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. The entire stock market is on MarketScreener. Enterprise Value, P/E Ratio, PEG, FCF, and many other Ratios. Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, announced terms for its IPO on Thursday. View (NKTX) real-time stock price, chart, news, analysis, analyst reviews and more. This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and A detailed overview of Nkarta, Inc. Compare with other stocks. See the latest Nkarta Inc Ordinary Shares stock price (NKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Nkarta | IPOScoop Nkarta Print Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of A high-level overview of Nkarta, Inc. Die Nkarta Aktie wird aktuell von 7 Analysten bewertet. Find out all the key statistics for Nkarta, Inc. (NKTX) stock, including real-time price, chart, key statistics, news, and more. The company upsized the deal on Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday. View the latest Nkarta Inc. 7lm54vv, lssp, braatp, suyk, n7lu, gl, wh6u0, njw0p, pqvq7, br0, gbmlgg, j3pi, dwzfhw, 1gvr, ybv6ft, uetss, 8oltio, awz, j9n, lwnm, lgom1, n61, auymii, mlr, crejpk, mki, xox, d8jno, bj, yct0,